Alumis Inc.
ALMS
Rangering i aksjer
#10174
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Aksjekurs
$6.41
Sist synkronisert: 2026-10-19
Markedsverdi
$830.25M
Endring (1 dag)
4.81%
Endring (1 år)
182.57%
Land
US
Handel Alumis Inc. (ALMS)
Kategori
Healthcare
Inntekter for Alumis Inc. (ALMS)
Inntekter i Mar 2025 TTM: $-268.52M
Ifølge Alumis Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-268.52M. I 2023 hadde selskapet et resultat på $-381.64M, en nedgang sammenlignet med resultatet i 2022, som var $-64.77M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Alumis Inc. fra 2021 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $-268.52M | 8.17% |
| 2024 | $-248.23M | -34.96% |
| 2023 | $-381.64M | 489.21% |
| 2022 | $-64.77M | 54.81% |
| 2021 | $-41.84M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | -2,064.46% |
US
|
|
| $-3.09B | 1,049.65% |
US
|
|
| $-4.02B | 1,395.70% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -826.45% |
NL
|
